Trials / Completed
CompletedNCT04102553
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
Phase III Study of F-18-PSMA-1007 vs F-18-Fluorocholine PET to Compare the Detection Rate of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- ABX advanced biochemical compounds GmbH · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F-18-PSMA-1007 | Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order. |
| DRUG | F-18-Fluorocholine | Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order. |
Timeline
- Start date
- 2019-03-06
- Primary completion
- 2020-10-30
- Completion
- 2021-03-19
- First posted
- 2019-09-25
- Last updated
- 2021-06-29
Locations
6 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04102553. Inclusion in this directory is not an endorsement.